Drug intelligence / Profile preview

PF-05241328

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

PF-05241328 is a novel, potent, and selective inhibitor of human Nav1.7 voltage-dependent sodium channels. It was developed for pain treatment but was ruled out due to its half-life and peak-to-trough ratios requiring high therapeutic indices. It is highly plasma protein bound.

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on PF-05241328.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-05241328.

Explore the full profile